Taken together, our findings suggest that the albuminuria-lowering effects of GLP-1 RAs observed in RCTs are also relevant in a general population of patients with type 2 diabetes with a lower cardiovascular and kidney risk profile. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.